Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Rating of “Buy” from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $6.33.

A number of brokerages recently commented on CNTX. Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. JMP Securities began coverage on Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price for the company. Finally, D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Wednesday, January 15th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. State Street Corp raised its stake in Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after acquiring an additional 19,800 shares in the last quarter. Clear Harbor Asset Management LLC raised its stake in Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after acquiring an additional 21,804 shares in the last quarter. Jane Street Group LLC acquired a new position in Context Therapeutics during the fourth quarter worth $29,000. Citadel Advisors LLC acquired a new position in Context Therapeutics during the fourth quarter worth $31,000. Finally, Millennium Management LLC raised its stake in Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock worth $188,000 after acquiring an additional 34,835 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Trading Up 0.3 %

CNTX opened at $0.84 on Thursday. Context Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.75. The stock has a market capitalization of $63.15 million, a price-to-earnings ratio of -0.93 and a beta of 2.06. The business has a 50 day moving average of $0.94 and a 200-day moving average of $1.58.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.